China IVD Regulatory Affairs Outsourcing

Bringing in vitro diagnostic (IVD) devices to the Chinese market is complex, and often overwhelming without the right support. From mandatory local testing to evolving technical guidelines and regulatory changes, navigating China’s National Medical Products Administration (NMPA) approval process demands specialized knowledge.

What's more, China’s regulatory environment requires in-country representation, Chinese-language documentation, and close coordination with local testing labs and authorities. For IVD manufacturers, this creates three key challenges: how to accelerate market access whilst ensuring full regulatory compliance and keeping operational costs under control.

Outsourcing regulatory affairs to a trusted local partner such as Cisema offers a practical and strategic solution.

China NMPA IVD Registration
Medical Device Registration Indonesia
Three professional women standing by a window, smiling and holding coffee cups during a casual conversation.

Why Outsource Regulatory Affairs for IVDs in China?

At Cisema, we serve as your dedicated regulatory affairs partner in China, helping you register, launch, and maintain your IVD devices in full compliance with NMPA regulations. With decades of experience, our experts manage your regulatory journey from start to finish, reducing your internal burden and helping you stay ahead of changes.

We act as your external regulatory team, managing everything from product registration to post-market surveillance (PMS), so you can focus on innovation and growth.

Key Benefits of Outsourcing with Cisema's Regulatory Experts

Local Expertise with Global Insight

Our deep understanding of Chinese and international regulatory frameworks ensures compliance strategies that fit your business goals.

Faster Market Entry

Avoid delays and streamline the approval process with our expert support and local testing coordination.

Cost-Efficient Operations

Minimize internal staffing needs and lower your regulatory overhead.

Focus on Core Capabilities

Free your internal teams from regulatory complexity to concentrate on R&D, production, and commercialization.

Access to Specialist Knowledge

Our team offers up-to-date insights on NMPA requirements and regulatory standards, helping you make informed decisions and avoid costly missteps.

Compliance & Risk Reduction

We help build compliant quality management systems, support audits, and manage documentation to reduce regulatory risk.

Independent & Transparent Service

We’re not a distributor. As a neutral third party, we work exclusively in your interest.

Our IVD Regulatory Outsourcing Services

Cisema offers end-to-end regulatory support tailored for IVD manufacturers seeking to enter or expand the Chinese market:

NMPA Registration Support

Type testing at NMPA-authorized labs
Clinical evaluation and dossier preparation
Submission for Class II and III IVDs
Pathways for innovative or urgent-use diagnostics

Legal Agent & In-Country Representation

Official Legal Agent with NMPA
Communication with Chinese regulatory authorities
Ongoing license maintenance and renewals

Post-Market Services

Adverse event monitoring and reporting
Change management and license updates
UDI compliance and tracking system setup

Quality & Compliance Management

Implementation of Chinese GMP for IVDs
Internal audits and CAPA planning
Risk management system development

Labeling & IFU Review

Chinese-language content verification
Barcode and UDI alignment
Format and regulatory review

Documentation & Control

SOPs, QMS documentation, and lifecycle management
Alignment with current NMPA regulations and expectations

Request a Proposal for IVD Regulatory Outsourcing Services

Let Cisema help turn your plans into reality.

Request Proposal

Useful Articles

View More

China Medical Device and IVD Registration FAQs: What Foreign Manufacturers Need to Know About NMPA Requirements

Get answers to common China medical device and IVD registration questions, from NMPA classification rules to testing and renewal requirements.

April 15, 2026
China Medical Device and IVD Registration FAQs: What Foreign Manufacturers Need to Know About NMPA Requirements
China Medical Device and IVD Registration FAQs: What Foreign Manufacturers Need to Know About NMPA Requirements

China IVD Risk Classification Explained: How NMPA Class Shapes Registration Pathways

Learn how China IVD risk classification works under NMPA rules and see common compliance pitfalls to avoid.

April 15, 2026
China IVD Risk Classification Explained: How NMPA Class Shapes Registration Pathways
China IVD Risk Classification Explained: How NMPA Class Shapes Registration Pathways
Previous
Previous

Explore Related Services

Whether you’re just starting out or are a blue-chip, access our wide range of services and outsourcing solutions to help your business thrive.

China IVD Product Approvals

We guide you through every step of the China IVD registration and filing process. We take care of compliance with NMPA requirements, advising you on the optimal China entry pathway, and helping you through the whole process.

NMPA Legal Agent

We are your authorized representative in China, and fulfill your registrations and filings as well as ensuring compliance with quality and PMS requirements.

China Clinical Trials

You may be required to provide supplementary clinical data on Chinese patients or conduct a full trial in China.Our clinical research team will advise you, prepare the study protocol and assist setting up the clinical trial in China.

NMPA IVD Type Testing

Our on-site test engineers coordinate and supervise type tests of your IVDs in NMPA-accredited laboratories.

Drug Device Combination Products

We assist with the classification, authorization, and compliance of combination products in China, whether drug or device led.

China IVD Quality Compliance

We help you achieve and ensure ongoing compliance with Chinese requirements.Our experts prepare and assist you for official NMPA inspections.

IVD PMS & Vigilance

The NMPA is placing greater focus on PMS such as more in-China sampling inspections and regular standard changes.

How We’ve Helped Clients with Our Expert Guidance

Read about how we work with clients to find solutions, bringing together deep industry knowledge with leading talent.

View More
April 18, 2026

China Manufacture License Renewal for Level A2 Pressure Vessels

How Cisema Supported Inox Torres Group, S.L. in Successfully Renewing its China Manufacture License (SELO) for Level A2 Pressure Vessels

The China Manufacture License (CML), also known as the SELO license, is a mandatory requirement for manufacturers of pressure equipment intended for the Chinese market. Inox Torres Group, S.L.’s manufacturing site produces high-pressure vessels falling under the Level A2 scope. This license ensures compliance with China’s stringent quality and safety regulations for special equipment.

The Challenge: Managing SELO Complexity for High-Risk Equipment

Renewing a SELO license for Level A2 pressure vessels required careful coordination across regulatory, technical, and cultural dimensions.

  • Navigating Regulatory Complexity
    Navigating the complex and evolving SELO regulatory framework, particularly for high-risk products under Level A2, required meticulous planning and real-time compliance updates.
  • Ensuring Audit Readiness
    Inox Torres Group, S.L. needed to ensure all documentation and procedures were fully up to date and to select an appropriate demo product that met inspection requirements.
  • Managing Inspector Expectations
    Success depended on understanding the unspoken cultural and procedural expectations of SELO inspectors, including hosting and on-site hospitality.

Our Solution: Full-Spectrum SELO Audit Support

Recognizing the high stakes of SELO license renewal, Inox Torres Group, S.L. engaged Cisema for comprehensive regulatory and strategic support.

  • Reviewed the Quality Management System
    Cisema led the review and upgrade of the customer’s quality management system in line with the latest Chinese requirements, including a comprehensive gap analysis and revision of key documentation.
  • Audit Simulation & Preparation
    A preparatory remote audit simulation was conducted, walking through every step of the audit to ensure full readiness ahead of the on-site inspection.
  • Delivered On-Site Bilingual & Regulatory Support
    During the on-site audit, Cisema provided continuous bilingual support, interpreting inspector questions in real time and translating regulatory nuances for the customer.
  • Provided Culturally Appropriate Inspector Hosting
    Cisema arranged culturally appropriate corporate hospitality, helping establish a respectful and positive tone for the inspection. The team remained onsite throughout all audit days, including the weekend, to ensure no detail was overlooked.

The Outcome: Successful Renewal Without Disruption

Through hands-on execution and close coordination, the SELO renewal process was completed smoothly and efficiently.

  • Secured CML Renewal with Full A2 Status
    Inox Torres Group, S.L. successfully renewed its China Manufacture License for pressure vessels, maintaining its Level A2 classification.
  • Executed the Project Efficiently
    Full regulatory preparation and audit execution were completed within six months.
  • Achieved Seamless Inspector Coordination
    SELO inspectors were hosted and coordinated smoothly, with culturally aligned engagement throughout the audit.
  • Secured Regulatory Continuity  
    The renewal avoided operational disruptions and ensured compliance with updated SELO requirements.

Expertise and Efficiency: Acting as an Extension of the Client Team

Cisema’s experienced consultants acted as an extension of Inox Torres Group, S.L.’s regulatory and quality teams, providing both regulatory expertise and strategic foresight. Inspector concerns were anticipated and addressed proactively, transforming a potentially stressful process into a streamlined, well-orchestrated engagement with Chinese authorities.

Hands-on mentoring throughout the project helped the customer gain confidence and clarity in managing future SELO audits.

Why Choose Cisema

  • Strategic Regulatory Expertise: Deep understanding of Chinese bureaucracy, evolving SELO requirements, and inspector expectations.
  • Mentorship & Training: Step-by-step guidance that supported the customer’s quality team throughout the process.
  • Corporate Hospitality Excellence: Culturally aligned hosting that supports successful audit outcomes in China.
  • Audit Readiness & Precision: Gap analysis, audit simulation, and documentation refinement to pass SELO reviews efficiently.
  • End-To-End Support: Full management of the audit process, from document revision to on-site interpretation.

Further Information

Explore Cisema’s China Special Equipment (SELO) Certification services.

Learn More
China Manufacture License Renewal for Level A2 Pressure Vessels
Previous
Previous

Latest Insights

View More

China radio frequency beauty devices regulated as Class III medical devices from April 1, 2024, onwards

China radio frequency beauty devices have new technical review guidelines issued to ensure that products are safe and effective

March 18, 2026
China radio frequency beauty devices regulated as Class III medical devices from April 1, 2024, onwards
China radio frequency beauty devices regulated as Class III medical devices from April 1, 2024, onwards

China medical device industry standards March 2023 update

China medical device industry standards March 2023 update covers 20 standards released by the NMPA for manufacturers to comply with.

March 18, 2026
China medical device industry standards March 2023 update
China medical device industry standards March 2023 update

Coronavirus product manual changes required for China

Coronavirus product manual changes are required by the NMPA in China. Notice No. 349 (2023) outlines important modifications for Coronavirus nucleic acids, antigens, and antibodies detection reagents.

March 18, 2026
Coronavirus product manual changes required for China
Coronavirus product manual changes required for China

China medical device registrations 2023 annual report issued

China medical device registrations 2023 annual report has been issued by the NMPA.

March 19, 2026
China medical device registrations 2023 annual report issued
China medical device registrations 2023 annual report issued

Revised Medical Device Clinical Trial Inspection Points Released by NMPA

China’s NMPA has released updated inspection principles for medical device clinical trials, effective May 1, 2025. Discover key changes, risk categories, and compliance strategies.

March 18, 2026
Revised Medical Device Clinical Trial Inspection Points Released by NMPA
Revised Medical Device Clinical Trial Inspection Points Released by NMPA

Navigating Compliance for Pet Disease Antigen Screening Products in China

Stay compliant with China’s latest regulations on pet disease antigen screening. Learn how MARA classifies veterinary diagnostic products and what it means for businesses.

March 18, 2026
Navigating Compliance for Pet Disease Antigen Screening Products in China
Navigating Compliance for Pet Disease Antigen Screening Products in China
Previous
Previous

Get in Touch with Our Life Sciences Team

With over 20 years of experience and a proven track record, Cisema is trusted by startups and global IVD leaders alike to manage China regulatory affairs with efficiency and precision.

Request Proposal